MI&T Congressi

MI&T Srl has consolidated over ten years of proven experience in the organization of congresses, conferences and medical-scientific courses and in the provision of specific services for medical-scientific associations, in Italy and abroad.

Our mission

 

MI&T Congressi
F

The Role of IO for Oncogene-Addicted NSCLC

By MI&T Congressi FEATURING Francesco Passiglia
By MI&T Congressi FEATURING Francesco Passiglia
42 views
August 20, 2024
Comments 0
Login to view comments. Click here to Login
3rd International Summit on Lung Cancer
11:28

Options for ALK+ NSCLC

MI&T Congressi

J. Lin

136 views
10:25

RET Inhibitors in NSCLC

MI&T Congressi

B. Besse

19 views
09:40

Potential Role of ADC in Early Stage NSCLC

MI&T Congressi

E. Felip

30 views
13:51

ADC as Targeted Therapy in NSCLC

MI&T Congressi

F. Hirsch

82 views
10:41

Adaptive Mechanisms of Resistance to G12C(OFF) Inhibitors in NSCLC

MI&T Congressi

C. Ambrogio

27 views
11:40

New Drugs for HER2 Deregulated NSCLC

MI&T Congressi

E. Smit

44 views
08:38

Options for Osimertinib-Resistant NSCLC

MI&T Congressi

T. Bivona

83 views
11:34

Next Generation Immunotherapies in NSCLC

MI&T Congressi

R. Soo

43 views
10:10

Pharmacology of ADC Classes in Lung Cancer

MI&T Congressi

M. Del Re

80 views
11:48

ADC in Pretreated NSCLC

MI&T Congressi

N. Aransay

49 views
14:38

Tumor Immune Microenvironment and Immunotherapy Resistance

MI&T Congressi

D. Sangiolo

47 views
09:15

Potential Mechanisms of Resistance to ADCs

MI&T Congressi

J. Bar

32 views
08:52

Optimal Duration of Immunotherapy in NSCLC

MI&T Congressi

G. Pasello

90 views
09:40

The Role of IO for Oncogene-Addicted NSCLC

MI&T Congressi

F. Passiglia

42 views
10:26

Biomarkers for IO in NSCLC

MI&T Congressi

B. Ricciuti

63 views
12:10

New Drugs as Maintenance Therapy After CRT in Stage III NSCLC

MI&T Congressi

F. Barlesi

111 views
08:52

Neoadjuvant Chemoimmunotherapy in Unresectable NSCLC

MI&T Congressi

I. Opitz

143 views
11:59

How the Experts Manage: ADC-Associated Toxicities in NSCLC

MI&T Congressi

N. Leighl

171 views
06:44

Anti-ALK NSCLC Agents as Adjuvant Therapy

MI&T Congressi

M. Chiara Garassino

73 views
11:40

Anti-EGFR Agents in the Adjuvant NSCLC Setting

MI&T Congressi

Y. Wu

22 views
08:20

MRD in Early Stage Oncogene-Addicted NSCLC

MI&T Congressi

N. Normanno

41 views
12:35

How the Experts Manage: Cardiotoxicity and IO in NSCLC

MI&T Congressi

J. Remon Masip

107 views
12:08

Drugging exon 20 Mutations in NSCLC

MI&T Congressi

L. Mezquita

108 views
08:03

ctDNA in NSCLC Immunotherapy

MI&T Congressi

C. Rolfo

88 views
07:37

How to Select EGFR-Mutated Patients for EGFR+CT Combo in NSCLC

MI&T Congressi

P. Janne

32 views
08:18

ADC in Combination With Immunotherapy for NSCLC

MI&T Congressi

S. Liu

211 views
08:53

IO Long-Term Survival in Advanced NSCLC

MI&T Congressi

R. A. Stahel

54 views
06:15

Selecting Patients for CTLA4 Therapy for NSCLC

MI&T Congressi

R. Dziadziuszko

40 views
11:40

New Immune Checkpoint Inhibitors in Lung Cancer

MI&T Congressi

S. Peters

195 views
09:36

How the Experts Treat: Neoadjuvant Immunotherapy for Resected NSCLC

MI&T Congressi

M. Provencio Pulla

84 views
12:47

How the Experts Treat: Adjuvant or Neoadjuvant Immunotherapy for NSC…

MI&T Congressi

T. Cascone

141 views
09:46

N2 Disease in NSCLC: Who Is Resectable?

MI&T Congressi

M. Brandão

125 views
10:58

Therapies for ROS1+ NSCLC

MI&T Congressi

L. Landi

78 views
08:17

Options for NTRK Rearranged NSCLC

MI&T Congressi

R. Ferrara

44 views
12:06

Maintenance IO in Stage III Unresectable NSCLC

MI&T Congressi

A. Dingemans

32 views
17:05

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

468 views
24:05

Neoadjuvant and Adjuvant Therapies in NSCLC: Are We Saving Lives?

MI&T Congressi

G. Scagliotti

177 views
07:55

MET Exon 14 Skipping Mutations in NSCLC

MI&T Congressi

O. Gautschi

178 views
13:19

Current Standards of Care in SCLC

MI&T Congressi

C. Rudin

221 views
14:12

Current and Future Options for Relapsed SCLC

MI&T Congressi

L. Paz-Ares

169 views
10:31

Immunotherapy for Patients With Mesothelioma

MI&T Congressi

J. Aerts

59 views
11:59

How the Experts Treat: Adjuvant Immunotherapy for Resected NSCLC

MI&T Congressi

D. Isla

81 views
09:42

Perspectives for NSCLC Patients Not Obtaining Complete Pathological …

MI&T Congressi

T. Mok

61 views
10:50

Current ADC Development in NSCLC

MI&T Congressi

H. Borghaei

178 views
14:12

Options for BRAF-Mutated NSCLC Patients

MI&T Congressi

D. Planchard

103 views
12:06

KRAS Inhibitors for Lung Cancer

MI&T Congressi

R. Rosell

192 views
25:03

Preventing Lung Cancer: Hope or Reality?

MI&T Congressi

U. Pastorino

57 views
31:11

Early Palliative Care in Lung Cancer

MI&T Congressi

D. Hui

42 views
09:12

How the Experts Treat: Neoadjuvant or Adjuvant Targeted Therapy in R…

MI&T Congressi

J. Naidoo

160 views
11:42

Surgery at the Time of Immunotherapy for Early Stage NSCLC

MI&T Congressi

J. Spicer

57 views
15:28

Radiotherapy for N2 Resected NSCLC

MI&T Congressi

C. Le Péchoux

29 views